Welcome to our dedicated page for Abivax S.A. SEC filings (Ticker: ABVX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Struggling to find the next clinical milestone hidden in Abivax SA’s dense SEC paperwork? Biotech disclosures pack pages of immunology data, cash-runway tables, and dilution scenarios that matter to every ABVX shareholder. Whether you are tracking obefazimod’s Phase III progress or weighing financing risk, the details often sit deep inside a 20-F, a sudden 8-K, or a Form 4 showing an executive stock purchase.
Stock Titan turns those complex documents into clear insights. Our AI-powered summaries translate Abivax’s annual report 10-K simplified explanations, break down each quarterly earnings report 10-Q filing, and flag 8-K material events explained in plain language—minutes after they hit EDGAR. Need real-time alerts on Abivax insider trading Form 4 transactions? You’ll see executive stock transactions Form 4 with context, alongside cash-flow trends and R&D spend extracted automatically. From proxy statement executive compensation tables to shelf-registration details, every filing type is covered and refreshed continuously.
Investors use these distilled insights to: monitor Form 4 insider transactions in real time before key data releases; compare trial-related expenses quarter over quarter; and understand how secondary offerings might affect share count. If you have ever typed “understanding Abivax SEC documents with AI” or “Abivax earnings report filing analysis,” this page is your answer. Access the full library of Abivax SEC filings explained simply, drill into specific numbers with one click, and make decisions backed by complete, up-to-date information—without wading through hundreds of technical pages.
Abivax SA reported interim results and updates through June 30, 2025 and subsequent events through August 2025. The company completed enrollment in its Phase 3 ABTECT program for ulcerative colitis on April 29, 2025 and announced positive July 22, 2025 induction results: the 50 mg once-daily dose met the FDA primary endpoint of clinical remission at Week 8 with placebo-adjusted rates of 19.3% (ABTECT-1, p<0.0001) and 13.4% (ABTECT-2, p=0.0001). For the six months ended June 30, 2025, R&D expenses rose to €77.9 million (up 21% vs prior year) driven by clinical progression; net financial loss was impacted by €6.9 million interest, €2.3 million FX losses and other non-cash items. Cash and cash equivalents were €60.9 million at June 30, 2025. A July 28, 2025 offering generated gross proceeds of €637.5 million (≈$747.5M) with estimated net proceeds ≈€597.2 million, which management expects, together with existing cash and note conversions, to fund operations into Q4 2027 and provide 12 months of runway after a planned NDA submission, assuming positive maintenance results. The statements were prepared on a going concern basis; shareholders' equity was negative at €48.3 million as of June 30, 2025. The company disclosed conversions of convertible instruments and potential material fair-value impacts in subsequent periods.
Deep Track Capital, Deep Track Biotechnology Master Fund and David Kroin report joint beneficial ownership of 3,480,144 Abivax SA ordinary shares (represented by American Depository Shares), equal to 4.78% of the outstanding class. The filing shows 0 shares of sole voting or dispositive power and 3,480,144 shares of shared voting and dispositive power, with the percentage calculated from 72,784,660 ordinary shares outstanding per the issuer's disclosure.
The reporting persons state the securities were not acquired to change or influence control of the issuer (other than activities solely in connection with a nomination under applicable rules). The statement is filed jointly by the two Deep Track entities and David Kroin.
FAQ
What is the current stock price of Abivax S.A. (ABVX)?
What is the market cap of Abivax S.A. (ABVX)?
